Identification and validation of 5-methylcytosine-associated genes in diffuse large B-cell lymphoma

Identification and validation of 5-methylcytosine-associated genes in diffuse large B-cell lymphoma

Blog Article

5-methylcytosine modifications play a significant role in carcinogenesis; however, studies exploring 5-methylcytosine-related genes in diffuse large B-cell lymphoma patients are lacking.In this study, we aimed to understand the potential role and clinical prognostic impact of 5-methylcytosine regulators in diffuse large B-cell lymphoma and identify a prognostic biomarker based on 5-methylcytosine-associated genes.Gene expression profiles and corresponding clinical information of diffuse large B-cell lymphoma patients and normal controls were obtained from The Cancer Genome Atlas, Gene Expression Omnibus, and Genotype-Tissue Expression databases.

Diffuse large B-cell lymphoma was divided into three clusters according to the 5-methylcytosine regulators, and differentially expressed genes were screened among the three clusters.Univariate Cox and Lasso-Cox regression analyses were used to screen prognostic genes and construct a prognostic risk Hoodie model.Kaplan-Meier curve analysis, univariate and multivariate Cox regression analyses, and time-dependent receiver operator characteristic curve analysis were used to evaluate prognostic factors.

GSVA was used to enrich potential pathways associated with 5-methylcytosine modification patterns.SsGSEA and CIBERSORT were used to assess immune cell infiltration.Six 5-methylcytosine-related genes (TUBB4A, CD3E, ZNF681, HAP1, IL22RA2, and POSTN) were used to construct a prognostic risk model, which was proved to have a good predictive effect.

In addition, univariate and multivariate Cox regression risk scores were independent prognostic factors for diffuse large B-cell lymphoma.Further analysis showed that the 5-methylcytosine risk score was significantly correlated with immune cell infiltration Screens and immune checkpoint of diffuse large B-cell lymphoma.Our study reveals for the first time a potential role for 5-methylcytosine modifications in diffuse large B-cell lymphoma, provides novel insights for future studies on diffuse large B-cell lymphoma, and offers potential prognostic biomarkers and therapeutic targets for patients with diffuse large B-cell lymphoma.